PGNX - Progenics Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.26
-0.08 (-1.50%)
At close: 4:00PM EDT

5.26 0.00 (0.00%)
After hours: 5:04PM EDT

Stock chart is not supported by your current browser
Previous Close5.34
Open5.31
Bid5.26 x 3200
Ask5.27 x 900
Day's Range5.19 - 5.35
52 Week Range3.62 - 9.42
Volume385,427
Avg. Volume807,201
Market Cap454.33M
Beta (3Y Monthly)2.60
PE Ratio (TTM)N/A
EPS (TTM)-0.90
Earnings DateOct 31, 2018 - Nov 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.50
Trade prices are not sourced from all markets
  • CNW Group2 days ago

    Court Upholds The Validity And Determined Actavis' Infringement Of Patent Protecting RELISTOR® Tablets

    BRIDGEWATER, N.J. and NEW YORK , July 17, 2019 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") and Progenics Pharmaceuticals (PGNX), announced today that the U.S. District Court of New Jersey upheld the validity and determined Actavis' infringement of a patent protecting RELISTOR® (methylnaltrexone bromide) tablets, expiring March 2031 . Defendant, Actavis Laboratories FL, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd, had challenged the validity of and had alleged non-infringement of Claims 2 and 5 of U.S. Patent No. 8,524,276, which protects the formulation of RELISTOR® tablets. Bausch Health is not aware of any other ANDAs filed with the FDA seeking approval of a generic version of RELISTOR tablets, and will continue to vigorously defend its intellectual property in these and other claims.

  • GlobeNewswire7 days ago

    Progenics Announces Preliminary Voting Results of Annual Meeting of Shareholders

    Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that, based on the preliminary voting results of its 2019 Annual Meeting of Shareholders, Progenics directors Mark R. Baker, Bradley L. Campbell, Karen J. Ferrante, David A. Scheinberg and Nicole S. Williams received a majority of the votes cast at the Annual Meeting, and Peter J. Crowley and Michael D. Kishbauch did not. In accordance with Progenics’ bylaws, Mr. Crowley and Mr. Kishbauch have each submitted a contingent resignation which will become effective only if the certification of the votes of the Annual Meeting confirms that they did not receive a majority of the votes cast and the Board of Directors accepts the resignation.  As required under the Company’s bylaws, the Nominating and Corporate Governance Committee is considering these matters and will recommend to the Board the action to be taken with respect to the tendered contingent resignations.  The Board will determine whether to accept such resignations, or what other action should be taken, in accordance with Progenics’ bylaws.

  • GlobeNewswire11 days ago

    Progenics Urges Shareholders to Vote Today “FOR” the Highly Qualified Director Candidates on the WHITE Proxy Card

    Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, encourages all shareholders to vote today “FOR” all of the Board’s highly qualified and engaged nominees online or by telephone by following the easy instructions on the “WHITE” Proxy Card. It is imperative that shareholders vote as soon as possible. All shareholders’ votes are extremely important, no matter how many shares they own.

  • PR Newswire11 days ago

    Velan Reminds Stockholders to Follow ISS' Recommendation by Voting "Against" Progenics Pharmaceuticals Directors Peter Crowley and Michael Kishbauch

    Agrees with ISS that "Board Level Change is Warranted, With the Ultimate Goal of Enhancing Shareholder Board Oversight" Urges Stockholders to Vote Before Thursday, July 11 Annual Meeting ALPHARETTA, ...

  • GlobeNewswire11 days ago

    Progenics Pharmaceuticals Strengthens Management Team with Appointment of Huw Jones as Vice President, Commercial

    Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced the appointment of Huw Jones to the newly created role of Vice President, Commercial. Mr. Jones has over 30 years of global experience leading commercial strategy and operations in the pharmaceutical industry, including almost two decades at Novartis Pharmaceuticals and its subsidiaries, most recently at Advanced Accelerator Applications SA and Novartis Oncology, Ltd. “We are pleased to welcome Huw to our growing commercial operations team to support Progenics’ maturing portfolio of innovative radiopharmaceuticals for the detection and treatment of cancer.

  • Here’s What Hedge Funds Think About Progenics Pharmaceuticals, Inc. (PGNX)
    Insider Monkey14 days ago

    Here’s What Hedge Funds Think About Progenics Pharmaceuticals, Inc. (PGNX)

    There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Jeff Ubben, George Soros and Carl Icahn think. Those hedge fund operators make billions of […]

  • PR Newswire18 days ago

    Velan Urges Stockholders To Follow ISS' Recommendation By Voting "Against" Progenics Pharmaceuticals Directors Peter Crowley And Michael Kishbauch

    ALPHARETTA, Ga., July 1, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other participants in its solicitation, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today issued a statement reminding stockholders that now is the time to demand accountability at Progenics and to follow the recommendation of Institutional Shareholder Services Inc. ("ISS"), a leading independent proxy advisory firm, by voting AGAINST the election of Progenics directors Peter Crowley and Michael Kishbauch at the Company's upcoming Annual Meeting of Stockholders scheduled to be held on July 11, 2019 (the "Annual Meeting"). In its report, ISS endorsed our call for change on the Progenics Board of Directors (the "Board"), highlighting the Board's seeming unwillingness to recognize the underperformance of the Company under its guidance and noting the Board's failure to hold management accountable for numerous operational and strategic missteps.

  • GlobeNewswire18 days ago

    Leading Independent Proxy Advisory Firm Glass Lewis Recommends Progenics Shareholders Vote “FOR” ALL of Progenics’ Director Nominees

    Glass Lewis Believes Velan’s “Fundamental Operational and Corporate Governance Case Fails to Bear Fruit” Glass Lewis Agrees the Current Settlement Offer is Fair and “Would.

  • PR Newswire21 days ago

    ISS Supports Velan's Call for Change by Recommending Stockholders Vote "Against" Progenics Pharmaceuticals Directors Peter Crowley and Michael Kishbauch

    ISS Believes Velan Presented a "Compelling Argument that Board Level Change is Warranted" to Enhance "Shareholder Board Oversight" ISS Highlights the Board's "Apparent Lack of ...

  • GlobeNewswire21 days ago

    Progenics Reiterates Targeted Directors’ Indispensable Experience and Leadership Critical to the Company’s Long-Term Success

    While we disagree with ISS’ conclusions, we are pleased that ISS recognizes the progress Progenics has made under the oversight of the Board. ISS recommends that shareholders vote FOR CEO Mark Baker, arguing that “the dissident [Velan]…has not presented a sufficient case for an immediate CEO change” and therefore recommends shareholders vote on management’s WHITE proxy card.

  • Benzinga21 days ago

    The Daily Biotech Pulse: Chiasma To Join R3K Index, EU Rejects Amgen's Osteoporosis Drug Application, Karuna IPO

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on June 27) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) (received ...

  • PR Newswire21 days ago

    Velan Clarifies Interactions with Progenics Pharmaceuticals' Board of Directors

    ALPHARETTA, Ga., June 28, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other participants in its solicitation, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today responded to more misleading statements by the Progenics Board of Directors (the "Board") regarding recent settlement discussions. The Board's attempts to distort the truth and avoid accountability at all costs continue to prove that its only defense is distraction and misdirection.

  • GlobeNewswire21 days ago

    Progenics Pharmaceuticals Details Recent Good Faith Efforts to Settle with Velan Capital

    Velan Rebuffed Very Reasonable Offer that Included a One Year Standstill, Designating Two New Independent Directors and an Incumbent Director Not Standing for Re-election in.

  • GlobeNewswire24 days ago

    Data Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting Highlights Potential of Progenics’ PSMA-Targeted Imaging Agent, PyL, in Detecting Prostate Cancer

    Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that results from studies highlighting the PSMA-targeted imaging agent, PyL, were presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting. “The data presented at SNMMI underscore the power of PyL to accurately detect prostate cancer, including high risk and biochemically recurrent disease where more precise imaging can change treatment decisions,” stated Asha Das, M.D., Chief Medical Officer of Progenics.

  • PR Newswire24 days ago

    Velan Releases Presentation Reiterating the Facts and Setting The Record Straight for Progenics Pharmaceuticals' Stockholders

    Highlights How the Board is Distorting the Truth, Mischaracterizing the Company's Current Dire State and Misleading Stockholders in an Attempt to Preserve the Troubling Status Quo Reminds Stockholders ...

  • GlobeNewswire25 days ago

    Independent Readers Using Progenics’ PSMA AI Demonstrated a Statistically Significant Improvement of Accuracy, Speed, and Reproducibility Over Readers Without PSMA AI

    NEW YORK, June 24, 2019 -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find,.

  • GlobeNewswire25 days ago

    Progenics Pharmaceuticals Files Supplemental Investor Presentation Rebutting Velan’s Latest Inaccurate Claims

    Progenics Pharmaceuticals, Inc. (PGNX) (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today filed a presentation with the U.S. Securities and Exchange Commission (“SEC”) in connection with its upcoming 2019 Annual Meeting (“Annual Meeting”) scheduled for July 11, 2019. The presentation addresses Velan Capital, L.P.’s (“Velan”) latest flawed arguments and is intended to supplement the investor presentation Progenics filed with the SEC on June 21, 2019 detailing the Company’s historic and ongoing actions to enhance shareholder value.

  • PR Newswire29 days ago

    Velan Releases Detailed Presentation on Progenics Pharmaceuticals

    Details the Persistent Performance, Execution, Governance and Transparency Shortcomings that Have Led to the Destruction of Significant Value Highlights the Need for True Accountability in the Boardroom ...

  • GlobeNewswire29 days ago

    Progenics Pharmaceuticals to Initiate a Basket Trial by Year End to Support an Expanded Label for AZEDRA® (iobenguane I 131) in Multiple MIBG Avid Neuroendocrine Tumors

    Progenics Pharmaceuticals, Inc. (PGNX), (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that the Company has reached alignment with the U.S. Food and Drug Administration (FDA) on the clinical development plan to pursue a tissue agnostic indication to support an expanded label for AZEDRA (iobenguane I 131) for the treatment of patients with unresectable or metastatic neuroendocrine tumors (NETs) who are MIBG avid. Following a Type B meeting with the FDA, the Company plans to conduct a basket study that will evaluate AZEDRA in patients with NETs that are MIBG avid, including gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and other NETs, with a dosing regimen that potentially enables outpatient administration.

  • PR Newswire29 days ago

    Velan Calls on Progenics Pharmaceuticals' Board to Back Up Recent Claims

    ALPHARETTA, Ga., June 20, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other participants in its solicitation, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today issued the following statement responding to the latest letter from Progenics' Board of Directors (the "Board") to stockholders. Velan calls on the Board to back up its claims by answering a few simple questions.  Progenics stockholders, the true owners of the Company, deserve answers and clarity.

  • Did Changing Sentiment Drive Progenics Pharmaceuticals's (NASDAQ:PGNX) Share Price Down By 46%?
    Simply Wall St.last month

    Did Changing Sentiment Drive Progenics Pharmaceuticals's (NASDAQ:PGNX) Share Price Down By 46%?

    This week we saw the Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) share price climb by 14%. But that is minimal...

  • GlobeNewswirelast month

    Progenics to Mail Letter to Shareholders

    Progenics Pharmaceuticals, Inc. (PGNX) (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, is mailing a letter to shareholders in connection with its upcoming 2019 Annual Meeting (“Annual Meeting”) scheduled for July 11, 2019. Shareholders of record as of the close of business on May 13, 2019 are eligible to vote at the Annual Meeting.

  • GlobeNewswirelast month

    Progenics Pharmaceuticals Announces Agreement with FUJIFILM Toyama Chemical Co. for Automated Bone Scan Index (aBSI) Product in Japan

    Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight, and follow cancer, today announced that EXINI, a wholly owned subsidiary of Progenics, has entered into a transfer agreement with FUJIFILM Toyama Chemical Co, Ltd. (FFTC) for the rights to Progenics’ Automated Bone Scan Index (aBSI) product in Japan for use under the name BONENAVI.

  • PR Newswirelast month

    Velan sets the Record Straight on Progenics Pharmaceuticals' Latest Misleading Statements

    Implores Stockholders to Follow Velan, a True "Fellow Shareholder," and Vote the GREEN Proxy Card Today AGAINST the Re-Election of Messrs. ALPHARETTA, Ga., June 17, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other participants in its solicitation, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today issued the following statement responding to certain misleading claims made by the Progenics Board of Directors (the "Board").